Subscribe to our free fortnightly newsletter and stay ahead with the latest news in HE

Leicester and GSK team up for cancer research

University of Leicester researchers and GSK collaborate to discover new cancer treatments

Posted by Rebecca Paddick | August 03, 2016 | Research

A collaboration between the University of Leicester and global pharmaceutical company GlaxoSmithaKline (GSK) has been established to discover and develop novel medicines to treat aggressive forms of blood cancer.

High grade non-Hodgkin’s lymphoma is one of the most common forms of blood cancer, with more than 5,000 new cases reported each year in the UK.

Professor Simon Wagner, from the Department of Cancer Studies, who is leading the project on behalf of the University of Leicester, said: “Currently these patients are treated with combination chemotherapy, but the 5-year survival rate of between 50 and 60 per cent shows that there is a long way to go before we can adequately manage these diseases. Amongst high-risk patient groups, particularly the elderly, outcomes are even worse partly because this population has a lower tolerance to the bone marrow toxicity associated with existing treatments. We see an urgent unmet need for new treatments that can attack the cancer, without causing this significant damage to the bone marrow.”

The new project is part of GSK’s Discovery Partnerships with Academia (DPAc) initiative, which brings together the insight and creativity of world-leading academics with the drug discovery expertise of GSK to create new medicines and bring them to the clinic.

The continued recognition and new investment from GSK illustrates the strength of the drug discovery team at Leicester

The aim of the new project is to discover and develop new molecules that can make a clinical impact in the treatment of patients with high-grade non-Hodgkin’s lymphoma. The new collaboration builds upon a previous GSK Discovery Fast Track Challenge project, which was awarded to Professor Wagner in December 2014 and was amongst the first projects of its type to launch in Europe. 

Professor Andrew Tobin from the University of Leicester Department of Molecular and Cell Biology and Director of the Leicester Drug Discovery and Diagnostics Centre which has supported the work to date said: “The continued recognition and new investment from GSK illustrates the strength of the drug discovery team at Leicester. By bringing together our cancer and structural biology specialists with the scale and experience of GSK we have been able to launch a full scale drug discovery programme from the University of Leicester aimed at delivering new treatments for a devastating cancer.”

Subscribe to our free fortnightly newsletter and stay ahead with the latest news in HE

Related stories

Most international students 'don't value' two-year degrees

University of Leicester opens international campus in China

Construction begins on £5.2m research hub at Buckingham Uni

Premium drinking water, sustainable and cost effective

Abertay appoints first Professor of Duty of Care in Sport

Student lifestyle - trends from around the world

Leicester unveils plans for £6m regional tech facility

High street vs campus

Moving with the times

Marketing to international students: improving engagement

Market place - view all

Prodisplay

Pro Display was born to innovate, changing the face of visual displ...

Tech Data

As one of the world's largest wholesale distributors of technology,...

Taplanes

Located in the village of Nidd, Taplanes began life as a subsidiar...

S&C Slatter

S&C Slatter have over 20 years experience as specialists in constru...

Sodexo

Our positioning in the services industry is original and unique. It...

Nationwide

Award winning online banking: whether it's current accounts, credit...